CY1124625T1 - Συνθεσεις προφαρμακου αριπιπραζολης - Google Patents
Συνθεσεις προφαρμακου αριπιπραζοληςInfo
- Publication number
- CY1124625T1 CY1124625T1 CY20211100753T CY211100753T CY1124625T1 CY 1124625 T1 CY1124625 T1 CY 1124625T1 CY 20211100753 T CY20211100753 T CY 20211100753T CY 211100753 T CY211100753 T CY 211100753T CY 1124625 T1 CY1124625 T1 CY 1124625T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aripiprazole prodrug
- aripiprazole
- surfactant
- prodrug
- prodrug compositions
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 5
- 239000000651 prodrug Substances 0.000 title abstract 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004372 aripiprazole Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038665P | 2014-08-18 | 2014-08-18 | |
| EP14181328 | 2014-08-18 | ||
| PCT/EP2015/068872 WO2016026822A1 (en) | 2014-08-18 | 2015-08-17 | Aripiprazole prodrug compositions |
| EP15750750.0A EP3182958B2 (en) | 2014-08-18 | 2015-08-17 | Aripiprazole prodrug compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124625T1 true CY1124625T1 (el) | 2022-07-22 |
Family
ID=51352472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100753T CY1124625T1 (el) | 2014-08-18 | 2021-08-23 | Συνθεσεις προφαρμακου αριπιπραζολης |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220079939A1 (enExample) |
| EP (2) | EP3182958B2 (enExample) |
| JP (1) | JP6571166B2 (enExample) |
| CN (3) | CN112641785A (enExample) |
| AU (1) | AU2015306198B2 (enExample) |
| BR (1) | BR112017002926A2 (enExample) |
| CA (1) | CA2957762A1 (enExample) |
| CY (1) | CY1124625T1 (enExample) |
| DK (1) | DK3508196T3 (enExample) |
| ES (1) | ES2884849T3 (enExample) |
| HR (1) | HRP20211271T1 (enExample) |
| HU (1) | HUE055711T2 (enExample) |
| IL (2) | IL292079B2 (enExample) |
| MX (1) | MX371417B (enExample) |
| PL (2) | PL3182958T5 (enExample) |
| PT (1) | PT3508196T (enExample) |
| RS (2) | RS58746B2 (enExample) |
| RU (1) | RU2705376C2 (enExample) |
| SI (2) | SI3182958T2 (enExample) |
| SM (2) | SMT202100481T1 (enExample) |
| WO (1) | WO2016026822A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2721270T5 (es) * | 2014-08-18 | 2022-07-21 | Alkermes Pharma Ireland Ltd | Composiciones de profármaco de aripiprazol |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| WO2017143017A1 (en) * | 2016-02-17 | 2017-08-24 | Alkermes Pharma Ireland Limited | Compositions of multiple aripiprazole prodrugs |
| CN110025572A (zh) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | 月桂酰阿立哌唑混悬剂及其制备方法 |
| AU2019230014B2 (en) * | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN110327296B (zh) * | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| TW202317118A (zh) | 2021-06-08 | 2023-05-01 | 日商中外製藥股份有限公司 | 含有二氫嗒-3，5-二酮衍生物的製劑 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| WO1997014407A1 (en) | 1995-10-17 | 1997-04-24 | Research Triangle Pharmaceuticals | Insoluble drug delivery |
| GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| DE60222160T2 (de) * | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| CA2543242C (en) * | 2003-10-23 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof |
| US20070148100A1 (en) * | 2005-09-15 | 2007-06-28 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| ES2639065T5 (es) | 2009-06-25 | 2023-01-30 | Alkermes Pharma Ireland Ltd | Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos |
| PL2685979T3 (pl) * | 2011-03-18 | 2017-02-28 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20 |
| CA2867137C (en) * | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
| AU2013235519C1 (en) * | 2012-03-19 | 2018-04-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
| NZ730571A (en) * | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
-
2015
- 2015-08-17 ES ES19154013T patent/ES2884849T3/es active Active
- 2015-08-17 PT PT191540137T patent/PT3508196T/pt unknown
- 2015-08-17 WO PCT/EP2015/068872 patent/WO2016026822A1/en not_active Ceased
- 2015-08-17 AU AU2015306198A patent/AU2015306198B2/en active Active
- 2015-08-17 DK DK19154013.7T patent/DK3508196T3/da active
- 2015-08-17 HU HUE19154013A patent/HUE055711T2/hu unknown
- 2015-08-17 SM SM20210481T patent/SMT202100481T1/it unknown
- 2015-08-17 CA CA2957762A patent/CA2957762A1/en active Pending
- 2015-08-17 SI SI201530711T patent/SI3182958T2/sl unknown
- 2015-08-17 RS RS20190505A patent/RS58746B2/sr unknown
- 2015-08-17 SM SM20190236T patent/SMT201900236T1/it unknown
- 2015-08-17 CN CN202011448652.3A patent/CN112641785A/zh active Pending
- 2015-08-17 RS RS20210956A patent/RS62232B1/sr unknown
- 2015-08-17 CN CN201580055491.2A patent/CN106794251B/zh active Active
- 2015-08-17 PL PL15750750.0T patent/PL3182958T5/pl unknown
- 2015-08-17 EP EP15750750.0A patent/EP3182958B2/en active Active
- 2015-08-17 EP EP19154013.7A patent/EP3508196B1/en active Active
- 2015-08-17 IL IL292079A patent/IL292079B2/en unknown
- 2015-08-17 RU RU2017108204A patent/RU2705376C2/ru active
- 2015-08-17 JP JP2017509024A patent/JP6571166B2/ja active Active
- 2015-08-17 HR HRP20211271TT patent/HRP20211271T1/hr unknown
- 2015-08-17 PL PL19154013T patent/PL3508196T3/pl unknown
- 2015-08-17 SI SI201531670T patent/SI3508196T1/sl unknown
- 2015-08-17 MX MX2017002029A patent/MX371417B/es active IP Right Grant
- 2015-08-17 CN CN202011416673.7A patent/CN112494492B/zh active Active
- 2015-08-17 BR BR112017002926A patent/BR112017002926A2/pt not_active Application Discontinuation
-
2017
- 2017-02-14 IL IL250607A patent/IL250607B/en unknown
-
2021
- 2021-08-23 CY CY20211100753T patent/CY1124625T1/el unknown
- 2021-10-12 US US17/450,683 patent/US20220079939A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124625T1 (el) | Συνθεσεις προφαρμακου αριπιπραζολης | |
| MX2024012899A (es) | Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias | |
| CY1121669T1 (el) | Συνθεσεις ινσουλινης ταχειας-δρασης | |
| CO2018011554A2 (es) | Formulaciones de nanopartículas lipídicas para componentes de cas/crispr | |
| EP3277769A4 (en) | Compositions and methods for the stabilization of clay-containing soils | |
| CL2017003151A1 (es) | Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas | |
| CY1122945T1 (el) | Αναλογα διοξολανιου της ουριδινη για τη θεραπεια του καρκινου | |
| IL284410A (en) | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| TW201614041A (en) | Compositions for electronic devices | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| EA201690900A1 (ru) | Новые тритерпенгликозиды в качестве подсластителей или усилителей подсластителей | |
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| UA119458C2 (uk) | Сполуки піридину пладієноліду та способи застосування | |
| EP3518955A4 (en) | TERT-IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT THEREOF | |
| CY1124286T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| EP3522854A4 (en) | NANOPARTICLE FORMULATIONS AND METHODS OF PRODUCING AND USING THE SAME | |
| CN106659716A8 (zh) | 阿吡莫德组合物及其使用方法 | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| SG11201911930SA (en) | Methods and compositions for substance use disorder vaccine formulations and uses thereof | |
| AU2016248452A8 (en) | Bordetella pertussis immunogenic vaccine compositions | |
| EP3236997A4 (en) | Dengue virus vaccine compositions and methods of use thereof | |
| CY1121594T1 (el) | Συνθεσεις προφαρμακου αριπιπραζολης | |
| JOP20200126A1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد |